BioFocus DPI and Oncodesign forge alliance to provide integrated oncology drug discovery services

28-Jul-2009 - United Kingdom

BioFocus DPI and Oncodesign announced that they have joined forces to offer a comprehensive oncology drug discovery service. The alliance combines BioFocus DPI’s target discovery and screening capabilities with Oncodesign’s experimental pharmacological and biomarker expertise in oncology. In addition, the partners will contribute their complementary medicinal chemistry expertise to form a drug discovery service specialized in the rapid generation of promising anticancer drug candidates.

“Oncodesign’s extensive experience in developing anticancer therapeutics complements BioFocus DPI’s medicinal chemistry and biology expertise, creating a focused oncology drug discovery offering that can move rapidly from hit finding to pre-clinical candidate,” said Chris Newton, Senior Vice President, BioFocus DPI. “As the industry’s understanding of disease pathways has grown considerably in recent years, the need for specialized drug discovery services has also grown. We expect that our current and future customers will benefit greatly from the synergies that this alliance offers.”

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance